LB Pharmaceuticals Inc Common Stock (LBRX) Stock Analysis

What LB Pharmaceuticals Inc Common Stock does

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Key metrics

ETFs linked to LBRX

Broad-market and Healthcare sector ETFs an investor holding LB Pharmaceuticals Inc Common Stock is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LBRX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for LB Pharmaceuticals Inc Common Stock?

LB Pharmaceuticals Inc Common Stock trades under the ticker LBRX on NASDAQ.

Which exchange is LBRX listed on?

LBRX is listed on NASDAQ.

What sector does LB Pharmaceuticals Inc Common Stock operate in?

LB Pharmaceuticals Inc Common Stock is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze LBRX in a portfolio?

PortView shows LBRX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.